MVA-BN Filo: Phase I started

Bavarian Nordic said the University of Oxford began an open-label, dose-escalation, U.K. Phase I trial to evaluate 2 doses of the company’s MVA-BN Filo and 3 doses of intramuscular cAd3-EBO Z from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) in about 60 volunteers ages 18-50. Subjects will receive cAd3-EBO Z alone or with a booster dose of MVA-BN Filo. ...